Search or
𝛼SK
𝛼SKbullish
Zai Lab IPO: Thoughts on Valuation, Risks and Upsides (Part 2)
2.2k Views14 Sep 2017 09:41
In our first insight, we covered the company's background, particularly its management team and its product pipeline.In this insight, we will...
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 6-minute read)
Related Insights
More »- [Zai LAB (ZLAB US, BUY, TP US$40) Review]: Past Is Holding ZLAB Back but Future Is What Matters
- ZaiLab's DLL3 ADC Is a Major Positive, but the Market Over-Reacted to Its Prospects
- [Zai LAB (ZLAB US, SELL, TP US$20) TP Change]: Two Positive News Drove up 2024 Growth Target
- [Zai LAB (ZLAB US) Target Price Change]: Demonstrating Directionally Business Model to Profit
- [Zai LAB (ZLAB US) Earnings Review]: Pretty Much the Same…Maintain SELL
Trending Collections
More »Trending Insights
More »- UK CPI Trips Into The Fall
- Gold Miners ETF (GDX US) Dec Rebalance: Zijin Gold Is a Miss; One Add Likely; US$4.1bn Trade
- Palliser Capital Goes Activist on LG Chem
- Korea’s Next Policy Play: NAV Discount Squeeze on Low‑Float Large Caps
- Gold: Reviewing Five Decades of Bull Markets Against an Overextended Backdrop
Top Unpaywalled Insights
More »- VEON (VEON US) 3Q25 Preview: Digital Revenue Mix & Margins Expanding
- Nvidia (NVDA.US): Problems Encountered in Land Acquisition to Establish Offshore Headquarters.
- OV #37 – From Chips to Ships: Markets Rattle as Trade War Escalates
- ACFTA 3.0: Greater Integration Likely, but Who Benefits?
- Beyond The Blue Chips: A Look At SGX’s iEdge Singapore Next 50
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Ascletis Pharma (1672 HK) IPO: First in Line23 Jul 2018
- Ascletis Pharma (歌礼制药) IPO: Three Valuation Risk Factors (Part 2)23 Jul 2018
- Ascletis Pharma (歌礼制药) IPO: Emerging Player in the Crowded HCV Drug Market16 Jul 2018
- Zai Lab IPO: Thoughts on Valuation, Risks and Upsides (Part 2)14 Sep 2017
- Zai Lab IPO: Experienced Team, Promising In-Licensing Drug Pipeline (Part 1)13 Sep 2017
x